Evidence map›Paper›PMID 24609760›Full record

ReviewClinical rheumatology2014

Hypereosinophilia and seroconversion of rheumatoid arthritis.

Rachel K Rosenstein, Richard S Panush, Neil Kramer, Elliot D Rosenstein

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Eosinophils in Autoimmune Diseases.Frontiers in immunology · 2017
    Review
  2. Article
  3. Eosinophilia.Primary care · 2016
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Rachel K RosensteinDepartment of Dermatology, Langone School of Medicine at New York University, New York, NY, USA.
Richard S Panush
Neil Kramer
Elliot D Rosenstein
Overlook Medical Center · USNew York University · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the intersection of atopy and autoimmunity, we present a patient with seronegative rheumatoid arthritis (RA) who developed hypereosinophilia, without evidence of other etiologies, as she became rheumatoid factor (RF) positive. Although the magnitude of eosinophilia in patients with RA has been thought to reflect the severity or activity of the RA, in our patient, eosinophilia developed at a time when the patient's synovitis was well controlled. Although eosinophilia may reflect associated drug hypersensitivity, discontinuation of the medications utilized to control our patient's disease, adalimumab and methotrexate, did not promote clinical improvement. Probably the most curious aspect of our patient was the concomitant development of rheumatoid factor seropositivity in the setting of previously seronegative RA. The temporal relationship between the development of peripheral eosinophilia and seroconversion suggests a possible connection between these events. We speculate that the T cell cytokine production that can induce eosinophilia may simultaneously activate RF production.

Indexed as

AdalimumabAged, 80 and overAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, RheumatoidAutoimmunityFemaleHumansHypereosinophilic SyndromeMethotrexateRheumatoid FactorAdalimumabAntibodies, Monoclonal, HumanizedAntirheumatic AgentsMethotrexateRheumatoid Factor

Identifiers

PMID24609760
OpenAlexW1979774220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.